Latest news

Latest Intelligence

• Deal Watch March 2017

  PureTech Health has entered an agreement with Novartis to advance two clinical stage programmes in the field of immuno-senescence. ... Novartis. PureTech Health. Licence. mTORC1 inhibitors in phase IIa. 25. InGeneron.

Latest appointments

• John LaMattina joins Frequency Therapeutics in advisory role

  Alongside his new role LaMattina will continue to serve as an independent non-executive director at PureTech Health.

• Former GSK exec joins PureTech Health

  Former GSK exec joins PureTech Health. Dr Atul Pande becomes chief medical officer. ... Boston, US-based PureTech Health has appointed Dr Atul Pande as its new chief medical officer, responsible for the firm's pipeline in immune, nervous and

• PureTech Health appoints chief scientific officer

  PureTech Health appoints chief scientific officer. Dr Joseph Bolen brings 30 years of clinical experience to the biotech. ... Boston, US-based PureTech Health has appointed Dr Joseph Bolen as its chief scientific officer.

• PureTech appoints Joseph Bolen as entrepreneur-in-residence

  PureTech appoints Joseph Bolen as entrepreneur-in-residence. And Vincent Hennemand joins as VP, company development and operations. ... Boston-based PureTech Health has appointed Joseph Bolen (pictured) as entrepreneur-in-residence. He previously served

• PureTech appoints new chief financial officer

  PureTech appoints new chief financial officer. Former Biogen VP Michael Maclean joins company. ... Boston-based PureTech Health has appointed Michael Maclean as its chief financial officer.